Can I read Everolimus and Exemestane in Breast Cancer on EtoBox?
Everolimus and Exemestane in Breast Cancer by Whilliamharvey is a document available to read on EtoBox.
What is Everolimus and Exemestane in Breast Cancer about?
Everolimus combined with exemestane improved progression-free survival compared to placebo plus exemestane in postmenopausal women with hormone receptor-positive advanced breast cancer previously treated with aromatase inhibitors. In a phase 3 trial of 724 patients, median progression-free survival was 6.9 months for everolimus plus exemestane versus 2.8 months for placebo plus exemestane based on local investigator assessments. Central assessment found median progression-free survival was 10.6 months versu
- Author
- Whilliamharvey
- Language
- EN